-
Metoprolol Tartrate for Selective β1-Blockade
2026-09-25
Use Metoprolol Tartrate to probe cardiac β1 signaling in cardiovascular assays, with practical guidance for compound preparation, controls, and response monitoring. A transplantation study also shows why β-blocker selectivity and model context matter when interpreting effects beyond the heart.
-
Latrunculin A for Actin Dynamics and Viral Assays
2026-09-25
Use Latrunculin A to perturb actin assembly rapidly and reversibly, then connect cytoskeletal changes to cell shape, motility, or infection readouts. A recent duck enteritis virus study provides a practical rationale for pairing actin disruption with targeted tests of the actin–myosin II network—while underscoring the need to separate direct effects from cell-health confounders.
-
nor-NOHA Acetate: Practical Research Workflows
2026-09-24
A hands-on guide to using nor-NOHA acetate to probe arginase activity, HepG2 phenotypes, and vascular function—with practical controls for compound handling and assay interpretation. It also explains how to explore arginine metabolism alongside CD36-driven AML immunosuppression without implying that the pathways are already proven to interact.
-
Acetylcholine Chloride for Gut–Brain Assays
2026-09-24
Use Acetylcholine Chloride as a defined cholinergic stimulus to test receptor-level responses alongside microbiota-driven gut–vagus–brain effects. This workflow translates recent Bacteroides fragilis findings into practical assay controls, fresh-solution handling, and troubleshooting strategies without treating an exogenous stimulus as a substitute for endogenous signaling.
-
NSP15 Screening Highlights Thymopentin and Oleuropein
2026-09-23
A 2021 structure-based screening study prioritized thymopentin and oleuropein as candidate binders of the SARS-CoV-2 RNA-processing enzyme NSP15, with molecular dynamics simulations supporting the stability of the modeled complexes. The results offer a computational starting point for experimental inhibitor testing, not evidence that either compound has demonstrated antiviral efficacy.
-
Naloxone Hydrochloride as a Causal Probe
2026-09-23
Explore how Naloxone hydrochloride can dissect opioid receptor signaling in withdrawal, anxiety, neural stem cell, and immune assays. This evidence-led guide connects the CCK-8 morphine-withdrawal study to more rigorous opioid addiction and withdrawal studies.
-
PRDX5 Acetylation in Retinal I/R Injury
2026-09-22
The reference study identifies PRDX5 acetylation as a functional modifier of retinal ischemia–reperfusion injury, linking this post-translational change to oxidative stress, mitochondrial dysfunction, and neuronal apoptosis. By combining an acute high intraocular pressure mouse model with OGD/R-treated R28 cells, the work suggests that preserving PRDX5 activity may be more informative than measuring PRDX5 abundance alone.
-
ECL Chemiluminescent Substrate Detection Kit Workflow
2026-09-22
A practical guide to applying hypersensitive ECL chemistry when conventional immunoblots cannot reliably resolve low-abundance targets. The workflow connects HRP-based detection with autophagy and lysosomal biology, while emphasizing controls, quantitative imaging, and troubleshooting.
-
FITC Goat Anti-Rabbit IgG (H+L) Antibody Guide
2026-09-21
The FITC Goat Anti-Rabbit IgG (H+L) Antibody is a fluorescein-conjugated secondary antibody for detecting rabbit primary antibodies in immunofluorescence, flow cytometry, and fluorescence microscopy. Its affinity-purified polyclonal design supports signal amplification, while defined storage conditions help preserve reagent performance.
-
α-Eudesmol Protects Against Focal Ischemic Brain Injury
2026-09-21
The reference study connected inhibition of ω-agatoxin IVA-sensitive presynaptic calcium channels with reduced glutamate overflow and protection from focal ischemic brain injury in rats. Its combined synaptosome, microdialysis, and middle cerebral artery occlusion design provides a useful mechanistic framework for interpreting Cav2.1-linked neuroprotection while also showing why channel selectivity must be tested carefully.
-
o-Agatoxin IVA and Cortical Excitotoxicity
2026-09-20
Lustig, Ahern, and Greenberg tested whether the P/Q-type calcium channel antagonist ω-agatoxin IVA could protect cortical neurons from excitotoxic injury triggered by veratridine, ouabain, or NMDA. The study found no reduction in LDH-defined toxicity, showing that inhibition of presynaptic glutamate release does not necessarily prevent downstream neuronal death.
-
o-Agatoxin IVA and Excitotoxicity in Cortical Neurons
2026-09-19
This study tested whether blocking P- and Q-type voltage-gated calcium channels with o-Agatoxin IVA could protect cultured cortical neurons from excitotoxic injury. Its central finding was negative but informative: inhibition of glutamate release or selected calcium-channel subtypes did not prevent toxicity caused by veratridine, ouabain, or NMDA, cautioning against equating reduced transmitter release with neuroprotection.
-
Acetylcholine Chloride in Cell Assays
2026-09-18
Learn how Acetylcholine Chloride, SKU B1596, can improve the control and interpretation of cholinergic stimulation in cell viability, proliferation, cytotoxicity, and gut–brain experiments. This scenario-based guide connects reagent handling, assay design, receptor biology, and recent gut-brain evidence without overstating what a cell assay can demonstrate.
-
Lithium, Exosomal Wnt10a, and Bone Regeneration
2026-09-18
This study identifies a mechanistic route by which lithium enhances BMSC osteogenesis: MARK2-associated Rab11a/Rab11FIP1 trafficking increases exosomal Wnt10a release and activates Wnt/β-catenin signaling. Lithium-conditioned exosomes and GelMA-based delivery improved osteogenic outcomes, providing a framework for cell-free bone-regeneration strategies while highlighting the need for careful pathway-specific validation.
-
Otilonium Bromide: From Target to Assay Design
2026-09-17
Otilonium Bromide is an antimuscarinic agent for dissecting cholinergic signaling in smooth muscle and neuroscience models. This guide moves beyond compound description to show how receptor perturbation, orthogonal readouts, and computational screening logic can improve assay decisions.